Savolitinib vs. Sunitinib in MET-driven PRCC.
AstraZeneca
AstraZeneca
Mayo Clinic
NeoImmuneTech
Hoffmann-La Roche
AstraZeneca
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of California, San Diego
AstraZeneca
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Revolution Medicines, Inc.
National Cancer Institute (NCI)
Exelixis
National Institutes of Health Clinical Center (CC)
AstraZeneca
AstraZeneca
University of Kentucky
AstraZeneca
Sanofi
Exelixis
University Health Network, Toronto
University of California, San Diego
Baptist Health South Florida
Verrica Pharmaceuticals Inc.
Pfizer
Hoffmann-La Roche
Numab Therapeutics AG
Regeneron Pharmaceuticals
HiberCell, Inc.
Boston Scientific Corporation
Intensity Therapeutics, Inc.
Alliance for Clinical Trials in Oncology
University of Utah
Sirtex Medical
Baptist Health South Florida
University of California, San Diego
Atara Biotherapeutics
BeiGene
Pfizer
Imunon
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Federation Francophone de Cancerologie Digestive
University of California, San Francisco
Advaxis, Inc.
Kyowa Kirin Co., Ltd.
Hoosier Cancer Research Network
Novartis
Steba Biotech S.A.